Production of tumor necrosis factor and granulocyte colony stimulating factor by bone marrow accessory cells in myelodysplastic patients

European Journal of Haematology

Volumn 56, Issue 3, 1996, Pages 148-152

  Mencoboni, M ^a,c   Castello, G ^a   Lerza, R ^a   Haupt, E ^b   Ballarino, P ^a   Cerruti, A ^a   Bogliolo, G ^a   Pannacciulli, I ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Hospital of Sestri Levante   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

BFU E; CFU GM; GM CSF; Myelodysplastic syndromes; Tumor necrosis factor

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROTEIN;

ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; STEM CELL; AGED; ANTIGEN PRESENTING CELL; BIOSYNTHESIS; BONE MARROW; CLASSIFICATION; CLONOGENIC ASSAY; COMPARATIVE STUDY; FEMALE; GENETICS; KARYOTYPING; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; AGED, 80 AND OVER; ANTIGEN-PRESENTING CELLS; BONE MARROW; COLONY-FORMING UNITS ASSAY; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029665164     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb01333.x     Document Type: Article

References (30)

1. OHMORI S, OHMORI M, YAMAGISHI M, OKUMA M, MDS-macrophage derived inhibitory activity on myelopoiesis of MDS abnormal clones. Br J Haematol 1993: 83: 388-391.
2. MECHAV S, NAGLER A, FLEISCHER-KURTZ G, TATARSKY I. Regulatory abnormalities in the marrow of patients with myelodysplastic syndromes. Br J Haematol 1989: 73: 158-164.
3. FUKUOKA T, FUJITA S. Leukemia-associated inhibitory activity in acute leukemia derived from MDS. Japanese J Med 1987: 26: 314-318.
4. OHMORI M, OHMORI S, UEDA Y, TOHYAMA K, YOSHIDA Y, UCHINO H. MDS-associated inhibitory activity on haematopoietic progenitor cells. Br J Haematol 1990: 74: 179-184.
5. OHMORI M, UEDA Y, MASUTANI H, et al. Myelodysplastic syndrome (MDS)-associated inhibitory activity on haematopoietic progenitor cells: contribution of monocyte-derived lipid containing macrophage (MDLM). Br J Haematol 1992: 81: 72-76.
6. CUKROVA V, NEUWIRTOVA R, CERMAK J, NEUWIRT J. Inhibitor of normal granulopoiesis produced by cells of MDS patients. Neoplasma 1989: 36: 83-89.
7. BENNETT JM, CATOVSKY D, DANIEL MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982: 51: 189-199.
8. VISANI G, ZAULI G, TOSI P, et al. Impairment of GM-CSF production in myelodysplastic syndromes. Br J Haematol 1993: 84: 227-231.
9. HERRMANN F, BAMBACH T, BONIFER R, et al. The suppressive effects of recombinant human TNF on normal and malignant hematopoiesis: synergism with interferon gamma. Int J Cell Cloning 1988: 6: 241-261.
10. VOLKERS B, GANSER A, GREHER J, CARLO STELLA C, HOELZER D. Effect of recombinant tumor necrosis factor on human hematopoietic progenitor cells. Onkologie 1989: 12: 109-115.
11. METCALF D. The granulocyte-macrophage colony-stimulating factors. Science 1985: 229: 16-22.
12. BURGESS AW, METCALF D. The nature and action of granulocyte-macrophage colony stimulating factors. Blood 1980: 56: 947-958.
13. BROXMEYER HE. Biomolecule-cell interactions and the regulation of myelopoiesis. Int J Cell Cloning 1986: 4: 378-405.
14. BRADLEY RT, METCALF D. The growth of bone marrow cells in vitro. Australian J Exp Biol Med Sci 1966: 44: 227-230.
15. ISCOVE NN, SIEBER F, WINTERHALTER KM. Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography of agarose conconavalin A. J Cell Biol 1974: 83: 309-320.
16. SENN JS, MESSNER HA, PINKERTON PH, et al. Peripheral blood blast cell progenitors in human preleukemia. Blood 1982: 59: 106.
17. JUVONEN E, PARTANEN S, KNUUTILA S, RUUTU T. Megakaryocyte colony formation by bone marrow progenitors in myelodysplastic syndrome. Br J Haematol 1986: 63: 331.
18. BERAN M, HAST R. Studies in human preleukemia. II. In vitro colony forming capacity in a regenerative anaemia with hypercellular bone marrow. Scand J Haematol 1978: 21: 139.
19. KOEFFLER HP, GOLDE DW. Cellular maturation in human preleukemia. Blood 1978: 52: 355.
20. GREENBERG PL, MARA B. The preleukemic syndrome: correlation of in vitro parameters of granulopoiesis with clinical features. Am J Med 1979: 66: 951-958.
21. FRANCIS GE, WING MA, MILLER EJ, BERNEY JJ, WONKE B, HOFFBRAND AV. Use of bone marrow culture in prediction of acute leukaemic transformation in preleukaemia. Lancet 1983: i: 1409-1412.
22. BOWEN D, YANCIK S, BENNETT L, CULLIGAN D, RESSER K. Serum stem cell factor concentration in patients with myelodysplastic syndromes. Br J Haematol 1993: 85: 63-66.
23. EVERSON MP, BROWN CB, LILLY MB. Interleukin-6 and granulocyte-macrophage colony-stimulating factor are candidate growth factors for chronic myelomonocytic leukemia cells. Blood 1989: 74: 1472.
24. GEISSLER K, HINTERBERGER W, BETTELHEIM P, et al. Colony growth characteristics in chronic myelomonocytic leukemia. Leuk Res 1988: 12: 373.
25. VERHOEF GEG, DESCHOUDER P, CEUPPENS JL. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992: 6: 1268.
26. NEGRIN RS, HAEUBER DH, NAGLER A, et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 1989: 110: 976-984.
27. VADHAN-RAJ S, KEATING M, LEMAISTRE A, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. New Engl J Med 1987: 317: 1545-1552.
28. GANSER A, VOLKERS B, GREHER J, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. A phase I/II trial. Blood 1989: 73: 31-37.
29. WILLEMZE R, VAN DER LELY N, ZWIERZINA H, et al. A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. Ann Haematol 1992: 64: 173-180.
30. SEIPELT G, GANSER A, DURANCEYK H, MAURER A, OTTMANN OG, HOELZER D. Induction of TNF-α in patients with myelodysplastic syndromes undergoing treatment with interleukin-3. Br J Haematol 1993: 84: 749-751.